CompletedNCT01518309
Long-Term Pimavanserin Safety for Parkinson’s-Related Psychosis
About this title
Read the official source — NCT01518309Medication studyUnited StatesSchizophrenia
Understand this study
- Listed locations
- DanburySee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: November 17, 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 39
- Sponsor
- ACADIA Pharmaceuticals Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- Not clearly listed
- Official registry ID
- NCT01518309
- Official title
Show the full official title
An Open-Label Safety Study of Pimavanserin in Parkinson's Disease Patients
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Danbury
Questions about this study
Who is behind this study?
The study sponsor is ACADIA Pharmaceuticals Inc.
Did this study involve medication?
Yes. The study involved medication, including pimavanserin tartrate (ACP-103).
Want to explore more studies?
Explore studiesRelated studies
Paliperidone Injections Compared With Oral Medication for Schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia